Bayer Cancels Taiwanese Project, Turns To US

24 December 1997

German chemical and pharmaceuticals group Bayer has decided to cancel aproject first proposed five years ago to build a plant in Taiwan worth NT$50 billion ($1.53 billion) and plans to move its investment to Baytown, Texas, USA, instead.

Bayer initially planned to build a chemical plant at Taichung harbour in central Taiwan, but the plan encountered objections from local residents, politicians and environmentalists. John Chen, deputy general manager of Bayer Taiwan, said that the company had spent more than $10 million on an environmental impact assessment, which it passed.

Govt Fails To Set Clear Rules Nevertheless, the magistrate-general of central Tai-Chung county, Liao Yung-lai, claimed that a plebiscite had to be held on the planned project. In a statement, Bayer noted that despite the fact that all applicable contracts and the environmental impact assessment had been finalized, "the Taiwan Provincial Parliament has chosen not to review the project....or set a clear time frame for the finalization of the approval process."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight